PDCD1 and neoplasm: To find novel therapeutic agents to combine with ICIs for tumor therapy, and because the tumor PD-L1 level is a determinant factor for anti-PD-L1/PD-1 therapy,22 we screened a common clinical drug library containing eight imidazoles, which have not been reported in anti-tumor immunity, to investigate their effects on tumor PD-L1 expression.